Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa

Acne

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

J Eur Acad Dermatol Venereol

Tzellos T, Giamarellos-Bourboulis EJ, van Straalen KR, Martorell A, Kirby B, Alavi A, Hayama K, Khattri S, Gulliver W, Sayed CJ, Davis L, Rolleri RL, Crater C, Pansar I, Lambert J, Zouboulis CC

doi: 10.1111/jdv.70356

Acne

Risk of New-Onset and Recurrent Depression and Anxiety Among Patients With Hidradenitis Suppurativa

JAMA Dermatol

Holgersen N, Rosenø NAL, Nielsen VW, Hjorthøj C, Nordentoft M, Garg A, Strunk A, Thyssen JP, Nilsson SF, Egeberg A, Thomsen SF

doi: 10.1001/jamadermatol.2025.2298

Further Publications Dermatology

Hair follicle stem cell fate supports distinct clinical endotypes in hidradenitis suppurativa

J Eur Acad Dermatol Venereol

Onfroy A, Jean-Louis F, Le Corvoisier P, Coulpier F, Muret K, Bonnet E, Arrouasse R, Boucle C, Abid S, Sbidian E, Bergqvist C, Wolkenstein P, Godot V, Deleuze JF, Lévy Y, Topilko P, Audureau E, Hue S

doi: 10.1111/jdv.70152

Psoriasis

Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared With Psoriasis

JAMA Dermatol

Wafae BGO, Charrow AP, Stein D, Barbieri JS, Noe MH

doi: 10.1001/jamadermatol.2025.2881

Acne

Prevalence of Comorbidities Among Pediatric Patients With Hidradenitis Suppurativa: A Meta-Analysis

JAMA Dermatol

Mohsen ST, Price EL, Lara-Corrales I, Levy R, Sibbald C

doi: 10.1001/jamadermatol.2025.1565

Acne

Neighborhood Socioeconomic Status and New Hidradenitis Suppurativa Diagnoses in a Single Health System

JAMA Dermatol

Chang AY, Sanchez-Anguiano ME, Supapannachart K, Amerson EH, Naik HB, Shiboski S, Derouen MC, Yazdany J

doi: 10.1001/jamadermatol.2025.1190

Psoriasis

Hidradenitis Suppurativa and Smoking, Obesity, Psoriasis, Inflammatory Bowel Disease, and Systemic Sclerosis: Results From A 2-Sample Mendelian Randomization Study

JAMA Dermatol

Kjærsgaard Andersen R, Riis PT, Zachariae C, Thomsen SF, Quin L, Dinh KM, Banasik K, Brunak S, Hansen T, Hjalgrim H, Sørensen E, Mikkelsen C, Ullum H, Nyegaard M, Bruun MT, Erikstrup C, Ostrowski SR, Eidsmo L, Lindhardt Saunte DM, Pedersen OBV, Jemec GBE

doi: 10.1001/jamadermatol.2025.5010

ImmunotherapyFurther Publications Dermatology

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Lancet

Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Peña AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M, CheckMate 9DW investigators

doi: 10.1016/S0140-6736(25)00403-9

Further Publications Rheumatology

Higher surgeon volume reduces early failure in first time revision of non-infected total knee arthroplasty: An analysis using data from the United Kingdom National Joint Registry

Knee Surg Sports Traumatol Arthrosc

Matthews AH, Gray WK, Evans JP, Evans JT, Lamb SE, Porteous A, Briggs T, Sabah SA, Alvand A, Toms AD, Price AJ

doi: 10.1002/ksa.12690

Related content

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

Risk of New-Onset and Recurrent Depression and Anxiety Among Patients With Hidradenitis Suppurativa

Hair follicle stem cell fate supports distinct clinical endotypes in hidradenitis suppurativa

Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared With Psoriasis

Prevalence of Comorbidities Among Pediatric Patients With Hidradenitis Suppurativa: A Meta-Analysis

Neighborhood Socioeconomic Status and New Hidradenitis Suppurativa Diagnoses in a Single Health System

Hidradenitis Suppurativa and Smoking, Obesity, Psoriasis, Inflammatory Bowel Disease, and Systemic Sclerosis: Results From A 2-Sample Mendelian Randomization Study

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Higher surgeon volume reduces early failure in first time revision of non-infected total knee arthroplasty: An analysis using data from the United Kingdom National Joint Registry